According to researchers, drugs that target envelope protein E on the SARS viral membrane could also be used to target a similar protein on COVID-19.
List view / Grid view
Severe Acute Respiratory Syndrome (SARS)
Filter the results
A study has demonstrated that the LY6E protein inhibits SARS-CoV-2 infection in human cell cultures, so a drug mimicking it could be a therapy for COVID-19.
Newly discovered antibodies found in the blood of recovered COVID-19 patients could provide robust protection against SARS-CoV-2, say researchers.
A group of small molecules called naphthalene-based PLpro inhibitors have been shown to block the activity of a SARS-CoV-2 protein, demonstrating potential as COVID-19 therapeutics.
Researchers reveal the main protease (Mpro) of SARS-CoV-2 is highly sensitive to disruption, therefore Mpro inhibitors could be a potential COVID-19 therapeutic.
Amid the rush to develop an effective vaccine against COVID-19, antibody therapy has become a major strategy to ameliorate and treat cases of severe disease. Armed with the capacity to neutralise pathogens and orchestrate the immune system, promising antibody candidates for multiple viral indications, including HIV, continue to emerge. Technology…
Researchers in the US describe how they utilised previously published scientific literature to guide the design of their potential COVID-19 vaccine.
Post-infection genome editing could be the cause of mutations in the SARS-CoV-2 virus responsible for the COVID-19 pandemic, driving its evolution.
An antibody called S309, identified in a blood sample from a SARS patient, inhibits related coronaviruses, including SARS-CoV-2, researchers have found.
Researchers have found that antibodies produced in response to SARS and COVID-19 are cross-reactive, but not cross protective in cells and mice.
In a new article, researchers highlight the need for treatments to combat the potentially lethal overreaction of the immune system in the progression of COVID-19.
Researchers have found that molecules from ticks called Evasins have the potential to halt cytokine storms, the leading cause of COVID-19 fatalities.
An antibody that neutralises both SARS-CoV and SARS-CoV-2 in cell cultures has been discovered by researchers and could be used to treat COVID-19.
According to researchers, ACE2 receptors disappear from lung cells during COVID-19, allowing small blood vessels to leak at the site of infection, presenting a new drug target.
Engineering antibodies found in a llama, researchers have developed a potential COVID-19 therapy which they say can neutralise SARS-CoV-2.